within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AC56_MeloxicamCombinations;

model MeloxicamCombinations
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.89,
    Cl = 1.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 15 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013166666666666667,
    Tlag = 10.200000000000001,
    Vdp = 0.007,
    k12 = 1.3333333333333334e-07,
    k21 = 1.3333333333333334e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>MeloxicamCombinations</td></tr><tr><td>ATC code:</td><td>M01AC56</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.42</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Meloxicam, in combination with other substances, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class, used primarily for its analgesic and anti-inflammatory effects in conditions such as osteoarthritis and rheumatoid arthritis. Meloxicam and its combinations are used in humans and some veterinary preparations. Meloxicam is approved for use in numerous countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for meloxicam, combinations, estimated for healthy adult individuals (sex not specified), typical oral administration.</p><h4>References</h4><ol><li><p>Naidoo, V, et al., &amp; Swan, GE (2008). The pharmacokinetics of meloxicam in vultures. <i>Journal of veterinary pharmacology and therapeutics</i> 31(2) 128–134. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.2007.00923.x\">10.1111/j.1365-2885.2007.00923.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18307504/\">https://pubmed.ncbi.nlm.nih.gov/18307504</a></p></li><li><p>Mzyk, DA, et al., &amp; Smith, GW (2023). Milk residues following multiple doses of meloxicam and gabapentin in lactating dairy cattle. <i>Journal of the American Veterinary Medical Association</i> 261(12) 1873–1879. DOI:<a href=\"https://doi.org/10.2460/javma.23.06.0329\">10.2460/javma.23.06.0329</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37734723/\">https://pubmed.ncbi.nlm.nih.gov/37734723</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01AC56 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end MeloxicamCombinations;
